Absence of behavioral abnormalities and neurodegeneration in vivo despite widespread neuronal huntingtin inclusions

被引:209
作者
Slow, EJ
Graham, RK
Osmand, AP
Devon, RS
Lu, G
Deng, Y
Pearson, J
Vaid, K
Bissada, N
Wetzel, R
Leavitt, BR
Hayden, MR
机构
[1] Univ British Columbia, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada
[2] Univ Tennessee, Grad Sch Med, Knoxville, TN 37920 USA
关键词
Huntington disease; mouse models; excitotoxicity; aggregates; fragment;
D O I
10.1073/pnas.0503634102
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
We have serendipitously established a mouse that expresses an N-terminal human huntingtin (htt) fragment with an expanded polyglutamine repeat(approximate to 120) under the control of the endogenous human promoter (shortstop). Frequent and widespread htt inclusions occur early in shortstop mice. Despite these inclusions, shortstop mice display no clinical evidence of neuronal dysfunction and no neuronal degeneration as determined by brain weight, striatal volume, and striatal neuronal count. These results indicate that htt inclusions are not pathogenic in vivo. In contrast, the full-length yeast artificial chromosome (YAC) 128 model with the identical polyglutamine length and same level of transgenic protein expression as the shortstop demonstrates significant neuronal dysfunction and loss. In contrast to the YAC128 mouse, which demonstrates enhanced susceptibility to excitotoxic death, the shortstop mouse is protected from excitotoxicity, providing in vivo evidence suggesting that neurodegeneration in Huntington disease is mediated by excitotoxic mechanisms.
引用
收藏
页码:11402 / 11407
页数:6
相关论文
共 39 条
[1]   A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila [J].
Apostol, BL ;
Kazantsev, A ;
Raffioni, S ;
Illes, K ;
Pallos, J ;
Bodai, L ;
Slepko, N ;
Bear, JE ;
Gertler, FB ;
Hersch, S ;
Housman, DE ;
Marsh, JL ;
Thompson, LM .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (10) :5950-5955
[2]   Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death [J].
Arrasate, M ;
Mitra, S ;
Schweitzer, ES ;
Segal, MR ;
Finkbeiner, S .
NATURE, 2004, 431 (7010) :805-810
[3]   Huntingtin aggregation and toxicity in Huntington's disease [J].
Bates, G .
LANCET, 2003, 361 (9369) :1642-1644
[4]   CFOS IMMUNOREACTIVITY IS ENHANCED WITH BIOTIN AMPLIFICATION [J].
BERGHORN, KA ;
BONNETT, JH ;
HOFFMAN, GE .
JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1994, 42 (12) :1635-1642
[5]   Neuronal dysfunction in a polyglutamine disease model occurs in the absence of ubiquitin-proteasome system impairment and inversely correlates with the degree of nuclear inclusion formation [J].
Bowman, AB ;
Yoo, SY ;
Dantuma, NP ;
Zoghbi, HY .
HUMAN MOLECULAR GENETICS, 2005, 14 (05) :679-691
[6]  
Carter RJ, 1999, J NEUROSCI, V19, P3248
[7]   Solubilization and disaggregation of polyglutamine peptides [J].
Chen, SM ;
Wetzel, R .
PROTEIN SCIENCE, 2001, 10 (04) :887-891
[8]   Mutation of the E6-AP ubiquitin ligase reduces nuclear inclusion frequency while accelerating polyglutamine-induced pathology in SCA1 mice [J].
Cummings, CJ ;
Reinstein, E ;
Sun, YL ;
Antalffy, B ;
Jiang, YH ;
Ciechanover, A ;
Orr, HT ;
Beaudet, AL ;
Zoghbi, HY .
NEURON, 1999, 24 (04) :879-892
[9]   Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation [J].
Davies, SW ;
Turmaine, M ;
Cozens, BA ;
DiFiglia, M ;
Sharp, AH ;
Ross, CA ;
Scherzinger, E ;
Wanker, EE ;
Mangiarini, L ;
Bates, GP .
CELL, 1997, 90 (03) :537-548
[10]   Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice [J].
Emamian, ES ;
Kaytor, MD ;
Duvick, LA ;
Zu, T ;
Tousey, SK ;
Zoghbi, HY ;
Clark, HB ;
Orr, HT .
NEURON, 2003, 38 (03) :375-387